Zydus and Lupin launched the generic version of Myrbetriq at risk in April 2025. Previous Post FIIs remain net sellers in Indian equities for second straight week in June Next Post Indian equities outperform global indices led by small-caps gains: Bandhan MF Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email, and website in this browser for the next time I comment.Post Comment
